

Roman Gulati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6028812/publications.pdf>

Version: 2024-02-01

123
papers

6,596
citations

81900

39
h-index

66911

78
g-index

126
all docs

126
docs citations

126
times ranked

9421
citing authors

#	ARTICLE	IF	CITATIONS
1	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	27.0	1,205
2	Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. <i>Journal of the National Cancer Institute</i> , 2009, 101, 374-383.	6.3	668
3	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016, 22, 369-378.	30.7	572
4	Quantifying the role of PSA screening in the US prostate cancer mortality decline. <i>Cancer Causes and Control</i> , 2008, 19, 175-181.	1.8	345
5	Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. <i>Nature Communications</i> , 2021, 12, 1426.	12.8	176
6	Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. <i>Cell Reports</i> , 2020, 31, 107669.	6.4	167
7	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2017, 167, 449.	3.9	160
8	Comparative Effectiveness of Alternative Prostate-Specific Antigen-Based Prostate Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 158, 145.	3.9	144
9	The prostate cancer conundrum revisited. <i>Cancer</i> , 2012, 118, 5955-5963.	4.1	125
10	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. <i>Annals of Internal Medicine</i> , 2014, 161, 104.	3.9	123
11	Influence of Study Features and Methods on Overdiagnosis Estimates in Breast and Prostate Cancer Screening. <i>Annals of Internal Medicine</i> , 2013, 158, 831.	3.9	117
12	Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends. <i>Biometrics</i> , 2008, 64, 10-19.	1.4	101
13	Is prostate cancer different in black men? Answers from 3 natural history models. <i>Cancer</i> , 2017, 123, 2312-2319.	4.1	100
14	Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. <i>Oncotarget</i> , 2014, 5, 9939-9951.	1.8	92
15	Expected population impacts of discontinued prostate-specific antigen screening. <i>Cancer</i> , 2014, 120, 3519-3526.	4.1	90
16	Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach. <i>Medical Decision Making</i> , 2008, 28, 323-331.	2.4	88
17	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	2.5	86
18	Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 122-127.	3.9	78

#	ARTICLE	IF	CITATIONS
19	Cancer Outcomes in DCIS Patients Without Locoregional Treatment. <i>Journal of the National Cancer Institute</i> , 2019, 111, 952-960.	6.3	76
20	Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. <i>Anti-Cancer Drugs</i> , 2010, 21, 423-432.	1.4	71
21	Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 229-237.	1.6	70
22	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. <i>JAMA Oncology</i> , 2016, 2, 890.	7.1	65
23	Limitations of Basing Screening Policies on Screening Trials. <i>Medical Care</i> , 2013, 51, 295-300.	2.4	63
24	Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation. <i>Journal of Clinical Oncology</i> , 2010, 28, 2668-2673.	1.6	61
25	The impact of PLCO control arm contamination on perceived PSA screening efficacy. <i>Cancer Causes and Control</i> , 2012, 23, 827-835.	1.8	61
26	Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling. <i>PLoS ONE</i> , 2013, 8, e78881.	2.5	60
27	Associations of obesity with triglycerides and C-reactive protein are attenuated in adults with high red blood cell eicosapentaenoic and docosahexaenoic acids. <i>European Journal of Clinical Nutrition</i> , 2011, 65, 808-817.	2.9	59
28	The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. <i>Cancer</i> , 2018, 124, 1197-1206.	4.1	56
29	Reconsidering the Trade-offs of Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2020, 382, 2465-2468.	27.0	53
30	Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2012, 18, 5471-5478.	7.0	52
31	<i>CDK12</i> -Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 382-392.	3.0	51
32	Individualized Estimates of Overdiagnosis in Screen-Detected Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt367-djt367.	6.3	47
33	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. <i>European Urology</i> , 2020, 77, 144-155.	1.9	46
34	Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yupik Eskimos. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 777-785.	4.7	45
35	Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. <i>Biostatistics</i> , 2010, 11, 707-719.	1.5	45
36	Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1412-1417.	5.0	43

#	ARTICLE	IF	CITATIONS
37	What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 740-750.	2.5	43
38	The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. <i>Prostate</i> , 2010, 70, 412-424.	2.3	42
39	Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1864-1870.	1.6	40
40	A Reality Check for Overdiagnosis Estimates Associated With Breast Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju315-dju315.	6.3	40
41	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , 2022, 81, 243-250.	1.9	40
42	Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. <i>International Journal of Cancer</i> , 2014, 135, 939-947.	5.1	39
43	Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. <i>BJU International</i> , 2012, 109, 706-712.	2.5	36
44	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 222-227.	2.5	33
45	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018, 168, 1.	3.9	33
46	Single cell transcriptomic analysis of prostate cancer cells. <i>BMC Molecular Biology</i> , 2013, 14, 6.	3.0	31
47	Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4592-4601.	7.0	31
48	Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes. <i>PLoS ONE</i> , 2014, 9, e104271.	2.5	30
49	Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv345-djv345.	6.3	30
50	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1667-1677.	7.0	30
51	Recent Trends in PSA Testing and Prostate Cancer Incidence. <i>JAMA Oncology</i> , 2016, 2, 955.	7.1	28
52	The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 18-18.	1.6	28
53	Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial. <i>Journal of the National Cancer Institute</i> , 2013, 105, 546-550.	6.3	26
54	Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. <i>American Journal of Epidemiology</i> , 2016, 184, 140-147.	3.4	26

#	ARTICLE	IF	CITATIONS
55	Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 808-815.	2.5	25
56	Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1013-1020.	6.3	23
57	Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. , 2022, 1, .		23
58	The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1336-1342.	6.3	22
59	Multicancer Early Detection: Learning From the Past to Meet the Future. <i>Journal of the National Cancer Institute</i> , 2022, 114, 349-352.	6.3	22
60	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. <i>European Urology</i> , 2022, 81, 576-585.	1.9	21
61	Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. <i>Clinical Cancer Research</i> , 2017, 23, 2301-2312.	7.0	20
62	Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. <i>Clinical Cancer Research</i> , 2014, 20, 5302-5310.	7.0	19
63	Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. <i>Histopathology</i> , 2017, 71, 406-414.	2.9	19
64	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. <i>Prostate</i> , 2019, 79, 701-708.	2.3	18
65	Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 677-682.	2.5	17
66	Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 10-16.	1.9	16
67	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <i>Annals of Internal Medicine</i> , 2018, 168, 608.	3.9	16
68	Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). <i>Contemporary Clinical Trials</i> , 2019, 81, 34-39.	1.8	15
69	Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. <i>Journal of Urology</i> , 2019, 202, 936-943.	0.4	14
70	Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1298-1304.	2.5	14
71	Oversimplifying Overdiagnosis. <i>Journal of General Internal Medicine</i> , 2014, 29, 1218-1220.	2.6	13
72	Racial disparities in prostate cancer survival in a screened population: Reality versus artifact. <i>Cancer</i> , 2018, 124, 1752-1759.	4.1	12

#	ARTICLE	IF	CITATIONS
73	Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. <i>American Journal of Epidemiology</i> , 2019, 188, 197-205.	3.4	12
74	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. <i>Oncotarget</i> , 2016, 7, 40690-40703.	1.8	12
75	A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer. <i>Prostate</i> , 2016, 76, 1285-1292.	2.3	11
76	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 77.	2.5	11
77	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. <i>PLoS ONE</i> , 2019, 14, e0211918.	2.5	10
78	Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels. <i>Journal of the National Cancer Institute</i> , 2020, 112, 384-390.	6.3	10
79	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	2.3	10
80	Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study. <i>American Journal of Epidemiology</i> , 2021, 190, 2064-2074.	3.4	9
81	Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. <i>Value in Health</i> , 2021, 24, 1111-1117.	0.3	9
82	Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa098.	2.9	9
83	Response. <i>Medical Care</i> , 2013, 51, 304-306.	2.4	8
84	Estimating and comparing cancer progression risks under varying surveillance protocols. <i>Annals of Applied Statistics</i> , 2018, 12, 1773-1795.	1.1	8
85	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. <i>Prostate</i> , 2021, 81, 418-426.	2.3	8
86	A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 38-44.	2.5	8
87	A Framework for Treatment Decision Making at Prostate Cancer Recurrence. <i>Medical Decision Making</i> , 2017, 37, 905-913.	2.4	6
88	Estimating the frequency of indolent breast cancer in screening trials. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1261-1271.	1.5	6
89	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239686.	2.5	6
90	Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis. <i>PLoS ONE</i> , 2014, 9, e111545.	2.5	6

#	ARTICLE	IF	CITATIONS
91	Deriving benefit of early detection from biomarker-based prognostic models. <i>Biostatistics</i> , 2013, 14, 15-27.	1.5	4
92	Measures of survival benefit in cancer drug development and their limitations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 122-127.	1.6	4
93	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e161-e167.	1.9	3
94	Overview of US Prostate Cancer Trends in the Era of PSA Screening. , 2009, , 3-14.		3
95	Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas. <i>JAMA Health Forum</i> , 2022, 3, e221116.	2.2	3
96	Insights from the PLCO trial about prostate cancer screening. <i>Cancer</i> , 2017, 123, 546-548.	4.1	2
97	Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia?. <i>American Journal of Epidemiology</i> , 2013, 178, 741-751.	3.4	1
98	Alternative Prostate Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 158, 778.	3.9	1
99	RE: A Model Too Far. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju058-dju058.	6.3	1
100	Active Surveillance for Ductal Carcinoma in Situ: Shining Light Into the Modeling Abyss. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv378.	6.3	1
101	A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden. <i>European Urology</i> , 2017, 71, 53-54.	1.9	1
102	When to Discuss Prostate Cancer Screening With Average-Risk Men. <i>American Journal of Preventive Medicine</i> , 2021, 61, 294-298.	3.0	1
103	Divining Harm-Benefit Tradeoffs of Magnetic Resonance Imaging-targeted Biopsy. <i>European Urology</i> , 2021, 80, 573-574.	1.9	1
104	A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 209-209.	1.6	1
105	Novel urine markers for diagnosing and monitoring non-indolent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16113-e16113.	1.6	1
106	Proportion of biochemically-recurrent prostate cancer patients with durable undetectable PSA after short-course androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 207-207.	1.6	1
107	1621 SINGLE CELL TRANSCRIPTOMIC PROFILING OF PROSTATE CANCER CELLS. <i>Journal of Urology</i> , 2011, 185, .	0.4	0
108	MP02-07 NOVEL URINE MARKERS FOR DIAGNOSING AND MONITORING NON-INDOLENT PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.4	0

#	ARTICLE	IF	CITATIONS
109	When Clinical Trials Disagree. <i>Journal of Urology</i> , 2018, 200, 506-507.	0.4	0
110	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. <i>Prostate</i> , 2018, 78, 1077-1083.	2.3	0
111	Impact of cancer screening on metastasis: A prostate cancer case study. <i>Journal of Medical Screening</i> , 2021, 28, 096914132198973.	2.3	0
112	Abstract 5242: Obtaining a transcriptomic profile of a single prostate cancer cell. , 2011, , .		0
113	Relationship of time to testosterone (T) and PSA rises during the first "off treatment" interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR).. <i>Journal of Clinical Oncology</i> , 2012, 30, 99-99.	1.6	0
114	Abstract 5237: Interrogating cell heterogeneity and dormancy in prostate cancer disseminated tumor cells. , 2012, , .		0
115	Abstract 4011: Single cell transcriptomic analysis identified a potential dormant signature in prostate cancer disseminated tumor cells. , 2014, , .		0
116	Improving the value of PSA prostate cancer screening with "smarter" strategies and increased use of active surveillance.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6616-6616.	1.6	0
117	Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance. , 2015, , .		0
118	Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16538-e16538.	1.6	0
119	Association of undetectable PSA with time to metastasis and survival after short-course androgen deprivation therapy for biochemically-recurrent prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17073-e17073.	1.6	0
120	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5081-5081.	1.6	0
121	Abstract 379: Supraphysiological testosterone inhibits tumor growth and is associated with inhibition of ARV7 signaling and DNA damage response in preclinical models of enzalutamide-resistant prostate cancer. , 2019, , .		0
122	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 943-943.	0.4	0
123	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 842-842.	0.4	0